AKT1 and rheumatoid arthritis: Ochaion et al. found that, in RA patients, the A3AR agonist CF502 mediated an anti-inflammatory effect by inhibiting the PI3K, PKB/Akt, and nuclear factor-kappaB (NF-κB) signaling pathway [6].